{"id":"letrozole-oral-product","safety":{"commonSideEffects":[{"rate":"50-60%","effect":"Hot flashes"},{"rate":"30-40%","effect":"Vaginal dryness"},{"rate":"20-30%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1444","moleculeType":"Small molecule","molecularWeight":"285.31"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Letrozole works by inhibiting the enzyme aromatase, which is involved in the biosynthesis of estrogen. By blocking this enzyme, letrozole reduces estrogen levels in the body, which can help slow the growth of hormone receptor-positive breast cancer cells.","oneSentence":"Aromatase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:42:15.937Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT06998407","phase":"PHASE1, PHASE2","title":"ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2025-08-20","conditions":"HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":380},{"nctId":"NCT05467891","phase":"PHASE2","title":"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Oana Danciu","startDate":"2022-09-13","conditions":"Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT06650748","phase":"PHASE2","title":"Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Peking University","startDate":"2025-05-01","conditions":"Breast Cancer, Early-stage Breast Cancer","enrollment":100},{"nctId":"NCT06075953","phase":"PHASE2","title":"DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2024-02-17","conditions":"Ductal Carcinoma in Situ","enrollment":400},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT03747042","phase":"PHASE2","title":"Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-11-27","conditions":"Breast Cancer Female","enrollment":61},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT07319429","phase":"PHASE2, PHASE3","title":"Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Endometrial Cancer, Fertility","enrollment":260},{"nctId":"NCT04886531","phase":"PHASE2","title":"Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers","status":"RECRUITING","sponsor":"Ruth O'Regan","startDate":"2022-07-21","conditions":"Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer","enrollment":30},{"nctId":"NCT03006172","phase":"PHASE1","title":"To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2016-12-13","conditions":"Breast Cancer, Solid Tumor","enrollment":200},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT04961996","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-08-27","conditions":"Early Breast Cancer","enrollment":4170},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT02520063","phase":"PHASE1, PHASE2","title":"Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2015-02-01","conditions":"Breast Cancer","enrollment":15},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT05867251","phase":"PHASE1, PHASE2","title":"Study of AVZO-021 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Avenzo Therapeutics, Inc.","startDate":"2023-08-30","conditions":"Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer","enrollment":430},{"nctId":"NCT03079011","phase":"PHASE3","title":"PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2017-03-22","conditions":"Metastatic Breast Cancer","enrollment":1017},{"nctId":"NCT05041842","phase":"PHASE2","title":"Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2021-12-17","conditions":"Metastatic Breast Cancer With a Isolated Brain Progression","enrollment":53},{"nctId":"NCT03959891","phase":"PHASE1","title":"AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2019-05-30","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT04553133","phase":"PHASE2","title":"PF-07104091 as a Single Agent and in Combination Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-09-16","conditions":"Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer","enrollment":154},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT05181033","phase":"PHASE2","title":"Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2021-12-27","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT06953882","phase":"PHASE2","title":"Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-07-09","conditions":"HER2 Negative Breast Cancer","enrollment":140},{"nctId":"NCT00001521","phase":"PHASE3","title":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1995-06-08","conditions":"Congenital Adrenal Hyperplasia (CAH)","enrollment":66},{"nctId":"NCT07000344","phase":"NA","title":"A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-07-01","conditions":"Ovarian Cancer","enrollment":70},{"nctId":"NCT06957379","phase":"PHASE2","title":"Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-02-29","conditions":"HR+/HER2- Advanced/Metastatic Breast Cancer","enrollment":78},{"nctId":"NCT03161353","phase":"PHASE2","title":"Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2017-06-26","conditions":"Breast Cancer","enrollment":377},{"nctId":"NCT05297617","phase":"PHASE2","title":"Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2022-10-12","conditions":"Breast Cancer","enrollment":696},{"nctId":"NCT04421547","phase":"PHASE3","title":"Efficacy of Letrozole in Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-06-22","conditions":"Epithelial Ovarian Cancer","enrollment":86},{"nctId":"NCT06525675","phase":"","title":"Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)","status":"COMPLETED","sponsor":"MedSIR","startDate":"2022-07-18","conditions":"Metastatic Breast Cancer, Advanced Breast Cancer, Luminal Breast Cancer","enrollment":419},{"nctId":"NCT03378297","phase":"EARLY_PHASE1","title":"IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2018-05-04","conditions":"Ovarian Cancer","enrollment":26},{"nctId":"NCT04539496","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sihuan Pharmaceutical Holdings Group Ltd.","startDate":"2018-05-22","conditions":"Metastasis Solid Tumors, Advanced Breast Cancer","enrollment":402},{"nctId":"NCT04282031","phase":"PHASE1, PHASE2","title":"A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Beta Pharma (Suzhou) Co., Ltd.","startDate":"2020-06-15","conditions":"Advanced Solid Tumor, HR+/HER2- Breast Cancer","enrollment":224},{"nctId":"NCT01296555","phase":"PHASE1","title":"A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2011-03-16","conditions":"Solid Cancers, Non-Hodgkin's Lymphoma","enrollment":674},{"nctId":"NCT04577001","phase":"PHASE2","title":"Letrozole in Patients With Hepatopulmonary Syndrome","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2021-02-18","conditions":"Hepatopulmonary Syndrome","enrollment":1},{"nctId":"NCT02448420","phase":"PHASE2","title":"Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"SOLTI Breast Cancer Research Group","startDate":"2015-07","conditions":"Metastatic Breast Cancer","enrollment":73},{"nctId":"NCT05861830","phase":"PHASE3","title":"Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-05-15","conditions":"Advanced Breast Cancer","enrollment":80},{"nctId":"NCT06181305","phase":"PHASE4","title":"Endometrial Preparation in Frozen Embryo Transfer Cycles","status":"UNKNOWN","sponsor":"Rahem Fertility Center","startDate":"2024-02-24","conditions":"IVF","enrollment":210},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT05157672","phase":"EARLY_PHASE1","title":"Evaluating the Pharmacokinetics and Drug Interaction Potential of the Botanical Dietary Supplement Cinnamon","status":"UNKNOWN","sponsor":"Washington State University","startDate":"2021-12-14","conditions":"Interaction Drug Food","enrollment":16},{"nctId":"NCT05304273","phase":"PHASE3","title":"Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages","status":"UNKNOWN","sponsor":"Calcutta National Medical College and Hospital","startDate":"2022-05-05","conditions":"Miscarriage","enrollment":120},{"nctId":"NCT05969184","phase":"PHASE2","title":"Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2021-12-25","conditions":"Breast Neoplasm Female","enrollment":94},{"nctId":"NCT03065621","phase":"PHASE2","title":"Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2017-07-05","conditions":"Breast Cancer Female","enrollment":100},{"nctId":"NCT03458221","phase":"PHASE2, PHASE3","title":"Signal TrAnsduction Pathway Activity Analysis in OVarian cancER","status":"RECRUITING","sponsor":"Gynaecologisch Oncologisch Centrum Zuid","startDate":"2023-01-31","conditions":"Recurrent Ovarian Cancer, Signal Transduction Pathway Deregulation, Therapy-Associated Cancer","enrollment":148},{"nctId":"NCT05789771","phase":"","title":"Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.","status":"COMPLETED","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2022-04-01","conditions":"HR+/HER2- Breast Cancer, Metastatic Disease, Аdvanced Disease","enrollment":136},{"nctId":"NCT05411380","phase":"PHASE2","title":"Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.","status":"UNKNOWN","sponsor":"wang shusen","startDate":"2022-10-03","conditions":"Breast Cancer","enrollment":73},{"nctId":"NCT00530868","phase":"PHASE2","title":"Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2007-10-08","conditions":"Breast Cancer, Cancer of the Breast, Breast Neoplasm","enrollment":75},{"nctId":"NCT03184090","phase":"PHASE2","title":"Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC","status":"COMPLETED","sponsor":"MedSIR","startDate":"2017-06-28","conditions":"Metastatic Breast Cancer","enrollment":33},{"nctId":"NCT01499160","phase":"PHASE2","title":"Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2012-05","conditions":"Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis","enrollment":7},{"nctId":"NCT02600923","phase":"PHASE3","title":"Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-04-15","conditions":"Advanced Breast Cancer Female","enrollment":131},{"nctId":"NCT03220178","phase":"PHASE4","title":"Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2017-07-24","conditions":"Breast Neoplasm","enrollment":532},{"nctId":"NCT05106712","phase":"NA","title":"Vitamin D Supplementation and Improvement of PCOS Therapy and IVF Outcomes in Infertile Saudi Women","status":"UNKNOWN","sponsor":"Umm Al-Qura University","startDate":"2021-11-01","conditions":"Female Infertility, Polycystic Ovary Syndrome, Pathologic Processes","enrollment":700},{"nctId":"NCT02213042","phase":"PHASE2","title":"Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-10-24","conditions":"Neoplasms, Breast","enrollment":42},{"nctId":"NCT02907918","phase":"PHASE2","title":"Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2017-06-30","conditions":"Breast Cancer, Cancer of Breast, Breast Carcinoma","enrollment":26},{"nctId":"NCT04047758","phase":"PHASE3","title":"Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer","status":"UNKNOWN","sponsor":"Shengjing Hospital","startDate":"2019-09-01","conditions":"Breast Cancer","enrollment":420},{"nctId":"NCT04666805","phase":"","title":"Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast","status":"UNKNOWN","sponsor":"First Hospital of China Medical University","startDate":"2020-07-01","conditions":"Breast Cancer","enrollment":1354},{"nctId":"NCT01684215","phase":"PHASE2","title":"A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-10-19","conditions":"Neoplasms, Breast Neoplasms","enrollment":61},{"nctId":"NCT04619914","phase":"NA","title":"the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women","status":"COMPLETED","sponsor":"Laylay Mohammed Khalleefah Alhibshi","startDate":"2019-03-01","conditions":"Endometrial Thickness, Pregnancy Rate","enrollment":160},{"nctId":"NCT01491737","phase":"PHASE2","title":"A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02-17","conditions":"Breast Cancer","enrollment":258},{"nctId":"NCT00721409","phase":"PHASE2","title":"Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-09-15","conditions":"Breast Cancer","enrollment":177},{"nctId":"NCT04088110","phase":"PHASE2","title":"Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer","status":"UNKNOWN","sponsor":"Fuzhou General Hospital","startDate":"2019-11","conditions":"Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast","enrollment":77},{"nctId":"NCT00756717","phase":"PHASE4","title":"Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer","status":"COMPLETED","sponsor":"Loyola University","startDate":"2008-02-14","conditions":"Breast Cancer","enrollment":22},{"nctId":"NCT03910712","phase":"PHASE2","title":"Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-06-01","conditions":"Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast","enrollment":250},{"nctId":"NCT02142868","phase":"","title":"Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate","status":"NO_LONGER_AVAILABLE","sponsor":"Pfizer","startDate":"","conditions":"Advanced Breast Cancer (Female)","enrollment":""},{"nctId":"NCT00728949","phase":"PHASE2","title":"A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-08","conditions":"Metastatic Breast Cancer","enrollment":93},{"nctId":"NCT03400683","phase":"NA","title":"Different Methods of Termination of Second Trimester Abortion","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2018-01","conditions":"Induction of Abortion","enrollment":150},{"nctId":"NCT03181919","phase":"NA","title":"Letrozole Step-up Protocol for Ovulation Induction in Infertile Women With PCOS","status":"COMPLETED","sponsor":"Benha University","startDate":"2016-01-01","conditions":"Infertility Poly Cystic Ovary","enrollment":90},{"nctId":"NCT01361945","phase":"PHASE1, PHASE2","title":"AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Texas Tech University Health Sciences Center, El Paso","startDate":"2011-07","conditions":"Breast Cancer, Metastatic Breast Cancer, HER-2 Positive Breast Cancer","enrollment":""},{"nctId":"NCT01626222","phase":"PHASE3","title":"4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Metastatic Breast Cancer","enrollment":301},{"nctId":"NCT00960960","phase":"PHASE1","title":"A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-08","conditions":"Breast Cancer","enrollment":71},{"nctId":"NCT01919229","phase":"PHASE2","title":"A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10","conditions":"Early Breast Cancer","enrollment":14},{"nctId":"NCT01129622","phase":"PHASE2","title":"Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)","status":"COMPLETED","sponsor":"Mount Sinai Hospital, Canada","startDate":"2008-10","conditions":"Breast Cancer","enrollment":16},{"nctId":"NCT01709370","phase":"PHASE2","title":"Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women","status":"UNKNOWN","sponsor":"Organisation for Oncology and Translational Research","startDate":"2012-02","conditions":"ER Positive, HER2 Negative Breast Cancer","enrollment":45},{"nctId":"NCT01375452","phase":"PHASE1","title":"Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2008-03","conditions":"Healthy","enrollment":36},{"nctId":"NCT01372982","phase":"PHASE1","title":"Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2008-04","conditions":"Healthy","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Letrozole Oral Product","genericName":"Letrozole Oral Product","companyName":"Gynaecologisch Oncologisch Centrum Zuid","companyId":"gynaecologisch-oncologisch-centrum-zuid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aromatase inhibitor Used for Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}